Patents by Inventor Georg Tiefenthaler

Georg Tiefenthaler has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antibodies specifically binding to human TSLPR and methods of use
    Publication number: 20120020988
    Abstract: An antibody specifically binding to human thymic stromal lymphopoietin receptor (TSLPR), characterized in comprising as heavy chain variable domain CDR regions a CDR1 region of SEQ ID NO:2 or 17, a CDR2 region of SEQ ID NO:3 or 10, and CDR3 region of SEQ ID NO:4, and as light chain variable domain CDR regions a CDR1 region of SEQ ID NO:6 or 12, a CDR2 region of SEQ ID NO:7, 13 or 15, and a CDR3 region of SEQ ID NO:8. is useful for the treatment of immunological diseases.
    Type: Application
    Filed: July 15, 2011
    Publication date: January 26, 2012
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: JOHANNES AUER, MARIA FUENTES, GUY GEORGES, HUBERT KETTENBERGER, HANS-WILLI KRELL, JENS NIEWOEHNER, GEORG TIEFENTHALER
  • POLYPEPTIDE PRODUCING CELLS
    Publication number: 20090311725
    Abstract: The current invention describes a nucleic acid comprising in a 5? to 3? direction a) a first nucleic acid encoding a heterologous polypeptide without an in frame stop codon, b) a second nucleic acid beginning with a 5? splice donor site and terminated by a 3? splice acceptor site comprising an in frame translational stop codon and a polyadenylation signal, and c) a nucleic acid encoding i) at least a fragment of a transmembrane domain, or ii) a signal peptide for a GPI-anchor.
    Type: Application
    Filed: May 15, 2007
    Publication date: December 17, 2009
    Inventors: Josef Endl, Erhard Kopetzki, Oliver Ploettner, Ursula Schwarz, Georg Tiefenthaler
  • Pyridylsulfonamide derivatives
    Patent number: 7625896
    Abstract: The present invention relates to the compounds of formula I: their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of such compounds, pharmaceutical compositions containing them and their manufacture, as well as the use of such compounds in the control or prevention of illnesses such as cancer.
    Type: Grant
    Filed: November 8, 2006
    Date of Patent: December 1, 2009
    Assignee: Hoffman-La Roche Inc.
    Inventors: Lothar Kling, Ulrike Reiff, Manfred Schwaiger, Georg Tiefenthaler, Wolfgang von der Saal, Thomas von Hirschheydt
  • Pyridylsulfonamide derivatives
    Publication number: 20070123513
    Abstract: The present invention relates to the compounds of formula I: their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of such compounds, pharmaceutical compositions containing them and their manufacture, as well as the use of such compounds in the control or prevention of illnesses such as cancer.
    Type: Application
    Filed: November 8, 2006
    Publication date: May 31, 2007
    Inventors: Lothar Kling, Ulrike Reiff, Manfred Schwaiger, Georg Tiefenthaler, Wolfgang von der Saal, Thomas von Hirschheydt
  • Styrylsulfonamides
    Patent number: 7208526
    Abstract: The present invention relates to the compounds of formula I: their pharmaceutically acceptable salts or esters, enantiomeric forms, diastereoisomers and racemates, the preparation of the above compounds, pharmaceutical compositions containing them and their manufacture, as well as the use of such compounds in the control or prevention of illnesses such as cancer.
    Type: Grant
    Filed: April 28, 2006
    Date of Patent: April 24, 2007
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Edward Boyd, Frederick Brookfield, Jonathan Gridley, Matthias Koerner, Manfred Kubbies, Raymond Lau, Ulrike Reiff, Georg Tiefenthaler, Wolfgang von der Saal, Timothy Woodcock
  • Heteroarylethenyl derivatives, their manufacture and use as pharmaceutical agents
    Patent number: 7208506
    Abstract: The present invention relates to compounds of formula I wherein R1, R2 and R3 are defined herein, their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of the above compounds, medicaments containing them and their manufacture, as well as the use of the above compounds in the control or prevention of illnesses such as cancer.
    Type: Grant
    Filed: June 29, 2006
    Date of Patent: April 24, 2007
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Edward Boyd, Frederick Brookfield, Jonathan Gridley, Manfred Kubbies, Raymond Lau, Ulrike Reiff, Georg Tiefenthaler, Wolfgang von der Saal, Thomas von Hirschheydt, Timothy Woodcock
  • Heteroarylethenyl derivatives, their manufacture and use as pharmaceutical agents
    Publication number: 20070010564
    Abstract: The present invention relates to compounds of formula I wherein R1, R2 and R3 are defined herein, their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of the above compounds, medicaments containing them and their manufacture, as well as the use of the above compounds in the control or prevention of illnesses such as cancer.
    Type: Application
    Filed: June 29, 2006
    Publication date: January 11, 2007
    Inventors: Edward Boyd, Frederick Brookfield, Jonathan Gridley, Manfred Kubbies, Raymond Lau, Ulrike Reiff, Georg Tiefenthaler, Wolfgang von der Saal, Thomas von Hirschheydt, Timothy Woodcock
  • Styrylsulfonamides
    Publication number: 20060270874
    Abstract: The present invention relates to the compounds of formula I: their pharmaceutically acceptable salts or esters, enantiomeric forms, diastereoisomers and racemates, the preparation of the above compounds, pharmaceutical compositions containing them and their manufacture, as well as the use of such compounds in the control or prevention of illnesses such as cancer.
    Type: Application
    Filed: April 28, 2006
    Publication date: November 30, 2006
    Inventors: Edward Boyd, Frederick Brookfield, Jonathan Gridley, Matthias Koerner, Manfred Kubbies, Raymond Lau, Ulrike Reiff, Georg Tiefenthaler, Wolfgang von der Saal, Timothy Woodcock
  • Amino-substituted dihydropyrimido[4,5-D]pyrimidinone derivatives
    Patent number: 7091345
    Abstract: Compounds of formula I are described. These compounds are protein kinase inhibitors, in particular they inhibit the src family tyrosine kinases. Thus, these compounds are useful for the treatment of diseases mediated by src tyrosine kinases, including cell proliferative disorders such as cancer. Also described are methods of making and using compounds of formula I as well as pharmaceutical compositions containing these compounds.
    Type: Grant
    Filed: October 30, 2003
    Date of Patent: August 15, 2006
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Jianping Cai, Nikolaos Dimoudis, Konrad Honold, Kin-Chun Luk, Stefan Scheiblich, Hilke Sudergat, Georg Tiefenthaler, Oliver Tonn
  • Combination of a gelatinase inhibitor and an anti-tumor agent, and uses thereof
    Publication number: 20040132739
    Abstract: The invention concerns combinations of a gelatinase inhibitor, e.g. Ro-28-2653 with a cytotoxic/cytostatic agent and its use for the treatment of tumors.
    Type: Application
    Filed: October 24, 2003
    Publication date: July 8, 2004
    Inventors: Thomas Friess, Hans-Willi Krell, Werner Scheuer, Georg Tiefenthaler
  • Amino-substituted dihydropyrimido[4,5-D]pyrimidinone derivatives
    Publication number: 20040087600
    Abstract: Compounds of formula I 1
    Type: Application
    Filed: October 30, 2003
    Publication date: May 6, 2004
    Inventors: Jianping Cai, Nikolaos Dimoudis, Konrad Honold, Kin-Chun Luk, Stefan Scheiblich, Hilke Sudergat, Georg Tiefenthaler, Oliver Tonn
  • Amphotropic retrovirus packaging cell line, process for its production and use thereof
    Patent number: 6475786
    Abstract: A titer of retroviral vectors of at least about 107 colony-forming units/ml cell culture supernatants is obtained using an amphotropic retroviral packaging cell line which contains functional gag, pol and env genes integrated into the genome in which the expression of the genes gag and pol is regulated independently of the expression of the env genes, wherein the genome of the said cell line contains one or two functionally active env genes.
    Type: Grant
    Filed: June 11, 2001
    Date of Patent: November 5, 2002
    Assignee: Roche Diagnostics GmbH
    Inventors: Claudio Bordignon, Bernhard Goller, Ruediger Rueger, Georg Tiefenthaler